quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:32:00·57d
PRRelease
Niagen Bioscience Inc. logo

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

NAGE· Niagen Bioscience Inc.
Health Care
Original source

Companies

  • NAGE
    Niagen Bioscience Inc.
    Health Care

Recent analyst ratings

  • May 27UpdateCanaccord Genuity$13.00

Related

  • PR1d
    Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
  • PR14d
    Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
  • PR23d
    Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
  • SEC35d
    Niagen Bioscience Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR35d
    Niagen Bioscience Increases Share Repurchase Program to $20 Million
  • PR36d
    Niagen Bioscience to Present at the 38th Annual ROTH Conference
  • PR37d
    Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
  • SEC50d
    Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022